Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement
2012 · Annals of Oncology · 291 citations
https://doi.org/10.1093/annonc/mds586
S
Séverine Guiu
Inserm(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
171
Papers
3.7K
Citations
30
h-index
64
i10-index
Séverine Guiu is an academic researcher from Inserm. The author has contributed to research in topics: Breast Cancer Treatment Studies & Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research. The author has an h-index of 30, co-authored 146 publications.
ORCID: 0000-0002-4901-6295Papers by this author
worksEfficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
2016 · Breast Cancer Research and Treatment · 118 citations
https://doi.org/10.1007/s10549-016-3828-6
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers
2018 · British Journal of Cancer · 76 citations
https://doi.org/10.1038/s41416-018-0142-6
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer
2013 · European Journal of Nuclear Medicine and Molecular Imaging · 68 citations
https://doi.org/10.1007/s00259-013-2616-3
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
2019 · Breast Cancer Research · 62 citations
https://doi.org/10.1186/s13058-019-1215-z
A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment
2021 · Theranostics · 53 citations
https://doi.org/10.7150/thno.58254
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat